Guidance for the treatment and prevention of obstetric-associated venous thromboembolism
Population
Pregnant or postpartum women at risk for or experiencing obstetric-associated venous thromboembolism (VTE)
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Use LMWH preferentially for obstetric VTE; reinforces prior consensus into actionable clinical guidance.
Structured PICO
P
Population
Pregnant or postpartum women at risk for or experiencing obstetric-associated venous thromboembolism (VTE)
I
Intervention
Prevention and treatment strategies for obstetric-associated VTE
This document provides practical clinical guidance on the prevention and treatment of obstetric-associated VTE based on existing guidelines and expert consensus.
Limitations
- Paucity of relevant high-quality research specific to pregnancy
- Recommendations are based largely upon observational studies and extrapolated from data in non-pregnant patients
- Lack of high-quality data results in a lack of consistency in guideline recommendations
Cite This Study
Bates et al. (2016) conducted a review in Obstetric-associated venous thromboembolism. Low molecular weight heparin (LMWH) was evaluated. Low molecular weight heparin is the preferred anticoagulant for the treatment and prevention of venous thromboembolism during pregnancy, except in patients with specific contraindications.